|
|||
2013-11-14 14:30:00 CET 2013-11-14 14:30:48 CET REGULATED INFORMATION Biotie Therapies - Major shareholder announcementsBiotie: Notification according to Chapter 9, Section 10 of the Finnish Securities Market ActBIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 14 November 2013 at 3.30 pm. Notification according to Chapter 9, Section 10 of the Finnish Securities Market Act Biotie Therapies Corp. ("Company" or "Biotie") has gained knowledge of a notification regarding changes in number of votes in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act, described below. The notification received by the Company concerns the changes in holdings of the Company's shares by Novo A/S as a result of the transactions carried out on 13 November 2013. As a result of these transactions, the aggregate holding of Novo A/S has decreased below 5 per cent of the total number of shares and votes of the Company. The change in holdings in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act of which the Company has gained knowledge of is described below: Name Number of shares Number of shares (%) of shares (%) of voting and voting rights and voting rights after rights after before after Novo A/S 26,141,552 17,441,554 3.85% 3.91% The registered number of shares in Biotie Therapies Corp. is 452,710,738. Of these shares 6,509,351 are held by the Company and the number of outstanding shares and voting rights attached to the shares amounts thus to 446,201,387. Turku, 14 November 2013 Biotie Therapies Corp. Timo Veromaa President and CEO For further information please contact: David Cook CFO email: david.cook@biotie.com Tel: +358 2 2748 900 Virve Nurmi Investor Relations Manager email: virve.nurmi@biotie.com Tel: +358 2 2748 911 DISTRIBUTION NASDAQ OMX Helsinki Ltd Main Media www.biotie.com [HUG#1743250] |
|||
|